Literature DB >> 29167830

Single injection dual phase CBCT technique ameliorates results of trans-arterial chemoembolization for hepatocellular cancer.

Pierleone Lucatelli1, Renato Argirò2, Stefano Bascetta1, Luca Saba3, Carlo Catalano4, Mario Bezzi4, Giovanni Battista Levi Sandri5,6.   

Abstract

Cone-beam CT (CBCT) application to the field of trans-arterial chemoembolization has been recently the focus of several researches. This imaging modality is performed with a rotation of the C-arm around the patient, without needs of patient repositioning. Datasets are immediately processed, obtaining volumetric CT-like images with the possibility of post-processing and reconstruction of images. Dual phase CBCT recently introduced in clinical practice consists in a first arterial acquisition followed by a delayed acquisition corresponding to a venous phase. The introduction of this feature has overcome the limit of single-phase acquisitions, allowing lesions characterization. Moreover these recent advantages have several intra-procedural implications. Detailed technical and acquisition parameters will be widely exposed in this review with particular attention to: catheter positioning, acquisition delay, injection parameters, patient positioning and contrast dilution. Comparison with standard of practice second line imaging [multidetector computer tomography (MDCT) and MDCT/arteriography] demonstrate the capability of detecting occult nodules providing some clinical implications thus potentially identifying a sub set of patients with aggressive disease behaviour. Other intra-procedural advantages of dual phase CBCT usage consist in a better tumor feeder visualization, reduction of proper DSA and fluoroscopic time, suggestion the presence of an extrahepatic parasitic feeder thus resulting in a more accurate treatment. Finally, the volumetrical intraprocedural evaluation of accumulation of embolic agent has proved to be correlate with treatment response if compared with MRI.

Entities:  

Keywords:  Cone-beam CT (CBCT); DEB-TACE; TACE; dual phase CBCT (DPCBCT); hepatocellular carcinoma (HCC); multidetector computer tomography (MDCT); rotational angiography

Year:  2017        PMID: 29167830      PMCID: PMC5676208          DOI: 10.21037/tgh.2017.10.03

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  32 in total

1.  Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation.

Authors:  Giovanni Battista Levi Sandri; Giuseppe Maria Ettorre; Marco Colasanti; Edoardo De Werra; Gianluca Mascianà; Daniele Ferraro; Giovanni Tortorelli; Rosa Sciuto; Pierleone Lucatelli; Giuseppe Pizzi; Ubaldo Visco-Comandini; Giovanni Vennarecci
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

2.  Superiority of CT arterioportal angiography to contrast-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2 cm.

Authors:  Soo Ryang Kim; Kenji Ando; Keiji Mita; Shuichi Fuki; Hirotsugu Ikawa; Yoshihiro Kanbara; Susumu Imoto; Toshiyuki Matsuoka; Yoshitake Hayashi; Masatoshi Kudo
Journal:  Oncology       Date:  2007-12-13       Impact factor: 2.935

3.  The forgotten place of radioembolization for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis.

Authors:  Giovanni Battista Levi Sandri; Quirino Lai; Pierleone Lucatelli
Journal:  Liver Int       Date:  2016-11-25       Impact factor: 5.828

4.  Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation.

Authors:  Giuseppe Maria Ettorre; Giovanni Battista Levi Sandri; Andrea Laurenzi; Marco Colasanti; Roberto Luca Meniconi; Raffaella Lionetti; Roberto Santoro; Pasquale Lepiane; Rosa Sciuto; Giuseppe Pizzi; Roberto Cianni; Rita Golfieri; Gianpiero D'Offizi; Adriano M Pellicelli; Mario Antonini; Giovanni Vennarecci
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

5.  Three-dimensional reconstructed rotational digital subtraction angiography in planning treatment of intracranial aneurysms.

Authors:  U Missler; C Hundt; M Wiesmann; T Mayer; H Brückmann
Journal:  Eur Radiol       Date:  2000       Impact factor: 5.315

6.  Comparison of three-dimensional rotational angiography with digital subtraction angiography in the assessment of ruptured cerebral aneurysms.

Authors:  Albrecht Hochmuth; Uwe Spetzger; Martin Schumacher
Journal:  AJNR Am J Neuroradiol       Date:  2002-08       Impact factor: 3.825

7.  Clinical application of transcatheter arterial chemoembolization combined with synchronous C-arm cone-beam CT guided radiofrequency ablation in treatment of large hepatocellular carcinoma.

Authors:  Zhi-Jun Wang; Mao-Qiang Wang; Feng Duan; Peng Song; Feng-Yong Liu; Yan Wang; Jie-Yu Yan; Kai Li; Kai Yuan
Journal:  Asian Pac J Cancer Prev       Date:  2013

8.  The value of combined soft-tissue and vessel visualisation before transarterial chemoembolisation of the liver using C-arm computed tomography.

Authors:  B C Meyer; M Witschel; B B Frericks; M Voges; W Hopfenmüller; K-J Wolf; F K Wacker
Journal:  Eur Radiol       Date:  2009-05-08       Impact factor: 5.315

9.  Usefulness of cone-beam computed tomography during ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinomas that cannot be demonstrated on angiography.

Authors:  Shiro Miyayama; Masashi Yamashiro; Miho Okuda; Yuichi Yoshie; Natsuki Sugimori; Saya Igarashi; Yoshiko Nakashima; Osamu Matsui
Journal:  Cardiovasc Intervent Radiol       Date:  2008-12-09       Impact factor: 2.740

10.  Computed analysis of three-dimensional cone-beam computed tomography angiography for determination of tumor-feeding vessels during chemoembolization of liver tumor: a pilot study.

Authors:  Frederic Deschamps; Stephen B Solomon; Raymond H Thornton; Pramod Rao; Antoine Hakime; Viseth Kuoch; Thierry de Baere
Journal:  Cardiovasc Intervent Radiol       Date:  2010-12       Impact factor: 2.740

View more
  6 in total

1.  Sequential dual-phase cone-beam CT is able to intra-procedurally predict the one-month treatment outcome of multi-focal HCC, in course of degradable starch microsphere TACE.

Authors:  Pierleone Lucatelli; Gianluca De Rubeis; Fabrizio Basilico; Luca Ginanni Corradini; Mario Corona; Mario Bezzi; Carlo Catalano
Journal:  Radiol Med       Date:  2019-08-31       Impact factor: 3.469

2.  Recent innovations in the management of hepatocellular cancer in the setting of liver transplantation: preface.

Authors:  Giovanni Battista Levi Sandri; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2018-02-06

3.  Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma.

Authors:  Sung-Hua Chiu; Ping-Ying Chang; Yu-Lueng Shih; Wen-Yen Huang; Kai-Hsiung Ko; Wei-Chou Chang; Guo-Shu Huang
Journal:  Drug Des Devel Ther       Date:  2020-11-17       Impact factor: 4.162

4.  Evaluation of three-dimensional iterative image reconstruction in C-arm-based interventional cone-beam CT: A phantom study in comparison with customary reconstruction technique.

Authors:  Shigeru Suzuki; Yoshiaki Katada; Tomoko Takayanagi; Haruto Sugawara; Takuya Ishikawa; Yuzo Yamamoto; Hiroo Wada
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

5.  Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study.

Authors:  Pierleone Lucatelli; Gianluca De Rubeis; Bianca Rocco; Fabrizio Basilico; Alessandro Cannavale; Aurelio Abbatecola; Pier Giorgio Nardis; Mario Corona; Stefania Brozetti; Carlo Catalano; Mario Bezzi
Journal:  BMC Gastroenterol       Date:  2021-02-03       Impact factor: 3.067

6.  Initial Experience of Drug-Eluting Bead-Transcatheter Arterial Chemoembolization After Lipiodol-Based Transcatheter Arterial Chemoembolization Failure for Patients with Advanced Hepatocellular Carcinoma.

Authors:  Kai-Cai Liu; Wei-Fu Lv; Dong Lu; Chang-Long Hou; Jun Xie; Yu-He Lu; Qi-Sheng Cao; Yu-Lin Tan; Ying-Zhan Zhang; Jie Liu
Journal:  Cancer Manag Res       Date:  2021-10-19       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.